Xero Pharmaceuticals

Xero Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing innovative treatments for primary axillary hyperhidrosis (excessive underarm sweating). The company's lead candidate, XERAXIS (NT-077), is a repurposed topical spray formulation of tiotropium bromide, a potent anticholinergic agent designed to act directly on sweat glands with minimal systemic absorption. Founded by dermatologist Wim Venema and pharmacist Ben Homan, Xero Pharmaceuticals aims to provide a best-in-class, self-administered, once-daily therapy to improve the quality of life for patients suffering from excessive sweating. The company is backed by Carduso Capital and has completed a first-in-human Phase 1 clinical trial in the Netherlands.